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Purpose: Some 10% of familial adenomatous polyposis (FAP) and
80% of attenuated polyposis (AFAP) cases remain molecularly
unexplained. We scrutinized such cases by exome-wide and
targeted methods to search for novel susceptibility genes.
Methods: Exome sequencing was conducted on 40 unexplained
(mainly sporadic) cases with FAP or AFAP from Finland. The
DNA mismatch repair (MMR) gene MLH3 (MutL Homolog 3) was
pinpointed and prompted a subsequent screen of ~1000 Swedish
patients referred to clinical panel sequencing for colon tumor
susceptibility.
Results: Three homozygous carriers of a truncating variant in
MLH3, c.3563C>G, p.Ser1188Ter, were identified among the index
cases from the Finnish series. An additional biallelic carrier of the
same variant was present in the Swedish series. All four patients
shared a 0.8-Mb core haplotype around MLH3, suggesting a
founder variant. Colorectal polyps from variant carriers showed no
instability at mono-, di-, tri-, or tetranucleotide repeats, in
agreement with previous findings of a minor role of MLH3 in
MMR. Multiple loci were affected by loss of heterozygosity,
suggesting chromosomal instability.
Conclusion: Our results show that a biallelic nonsense variant of
MLH3 underlies a novel syndrome with susceptibility to classical or
attenuated adenomatous polyposis and possibly extracolonic
tumors, including breast cancer.
Genetics inMedicine (2019) 21:1868–1873; https://doi.org/10.1038/s41436-
018-0405-x
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INTRODUCTION
Familial adenomatous polyposis (FAP, MIM 175100) is
characterized by multiple polyps in the colon and rectum
and an increased risk of colorectal cancer. Most patients with
classical FAP (polyp count at least 100) show heterozygous
pathogenic germline variants in the APC gene.1 Alterations in
the extreme 5’ or 3’ ends or the alternatively spliced exon 9 of
APC are associated with attenuated disease (AFAP, 10–100
polyps). (A)FAP-like polyposis may also result from patho-
genic sequence changes in various other genes, including
heterozygous variants in POLE and POLD1 (polymerase
proofreading-associated polyposis; MIM 615083 and 612591,
respectively), or homozygous variants in MUTYH (MIM
608456), NTHL1 (MIM 616415), and MSH3 (MIM 617100)
(ref. 1). Significant proportions of polyposis cases (10–80%
depending on polyp count) remain molecularly unexplained,2
encouraging searches for novel susceptibility genes.
Accurate molecular and clinical classification of conditions
with colorectal polyposis is a prerequisite for appropriate
genetic counseling and testing to guide patient management
and colorectal cancer prevention. To this end, we undertook
an exome sequencing study of 40 index cases from a cohort
with adenomatous polyposis from Finland in which patho-
genic variants in known polyposis-associated genes had been
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excluded.2 Results from this cohort, supplemented with panel
sequencing data from some 1000 cases with various colorectal
phenotypes from Sweden, unravel a novel polyposis syndrome
associated with biallelic germline nonsense variant of MLH3
(MutL Homolog 3).
MATERIALS AND METHODS
Patient cohorts and strategies to screen for pathogenic
germline variants
The patient series investigated are described in Supplementary
Materials and Methods and schematically depicted in Fig. 1a.
In the first phase, blood DNAs from 40 unrelated cases/
families with adenomatous polyposis from Finland, without
any detectable pathogenic sequence changes in known
polyposis-associated genes2 and in most cases sporadic at
presentation, were submitted to exome sequencing (ES).
Based on polyp count (with 100 polyps as a divider), 14
represented FAP and 26 AFAP. Guided by the findings from
the Finnish polyposis cohort, 829 patients from Sweden,
referred to Cancer Genetics Counseling clinics for a suspected
hereditary colorectal cancer syndrome, were analyzed for
MLH3 variants from panel sequencing data. Variants with
allele frequency below 0.003 (gnomAD), nonsynonymous
(frameshift, stop gained/lost, missense, disrupting donor/
acceptor site variants), and predicted pathogenic with at least
five of six programs assessing protein function in silico were
selected. The recurrent MLH3 c.3563C>G, p.Ser1188Ter
variant was further characterized by studying constitutional
DNA (haplotype analyses for shared versus independent
origin) and RNA (primer extension and cloning analyses for
nonsense-mediated RNA decay). Additionally, tumor tissues
from variant carriers were examined for microsatellite
instability (MSI), loss of heterozygosity (LOH)/allelic imbal-
ance (AI), CpG island methylator phenotype (CIMP), and
MMR protein expression (see Supplementary Materials and
Methods). Written informed consent preceded study partici-
pation and sample donation. This study was approved by the
institutional review board of the Helsinki University Central
Hospital (Helsinki, Finland) and by the local ethics commit-
tees of the Universities of Gothenburg and Lund, Sweden.
RESULTS
Identification of a recurrent germline variant in MLH3
Forty index cases with unexplained adenomatous polyposis
from Finland were investigated by exome sequencing to
dissect the underlying genes (Fig. 1a). After filtering out
variants common in the population and those unlikely to be
pathogenic (see “Materials and methods”), a recurring
nonsense variant affecting the DNA mismatch repair
(MMR) gene MLH3 (c.3563C>G, p.Ser1188Ter) (Table S1)
was observed in four families (Fig. 1b). The index individuals
from families 158, 168, and 177 were homozygous for the
variant (Figure S1). Polyposis was attenuated in the first one
and profuse in the latter two. The index person from family
1007 was heterozygous for the variant and showed mild
polyposis. The variant is absent in disease- or locus-specific
databases and rare in the population (allele frequency
0.0002603 in gnomAD and 0.00238 in Finns based on SISu;
no homozygotes reported).
Our subsequent literature search identified a recent study
on 91 Swedish cases referred to clinical panel sequencing for
FAP or Lynch syndrome (LS, MIM 120435 and related).3 A
sporadic case with apparently classical FAP (case IV:69
[ref. 3], who is the index individual of SWE family in Fig. 1b)
was diagnosed with the homozygous MLH3 p.Ser1188Ter
variant. Prompted by this finding, the entire MLH3 gene was
investigated in an additional cohort of 829 Swedish cases
referred to clinical laboratory screening for a suspected
hereditary colorectal cancer syndrome (Fig. 1a). No additional
cases with homozygous pathogenic or likely pathogenic
MLH3 variants were found, and no concomitant nonsynon-
ymous variants in MLH3 were detected in any of the patients
(Table S2). Despite looking like unrelated families, the four
Finnish cases and the single Swedish case with the MLH3 p.
Ser1188Ter variant all shared a 0.8-Mb haplotype around
MLH3 (Fig. 2a), suggesting origin from a common ancestor.
The variant was absent in cohorts of nonpolypotic colon
cancer (Fig. 1a).
Molecular characteristics of the MLH3 founder variant
The MLH3 p.Ser1188Ter variant causes an immediate stop of
translation, leading to the loss of the MLH1 binding domain
of MLH3 (Fig. 2b). The variant was associated with nonsense-
mediated RNA decay by primer extension and cloning
experiments (Figure S2). While none of the commercially
available MLH3 antibodies tested for immunohistochemistry
produced staining patterns of sufficient specificity, MSI results
were unequivocal: no single tumor (adenoma or carcinoma,
among a total of eight tumors investigated) from theMLH3 p.
Ser1188Ter variant carriers revealed any MSI at mono-, di-,
tri-, or tetranucleotide repeats, either by conventional
polymerase chain reaction (PCR) (Fig. 2c) or small pool
PCR. Instead, 8 of 15 di-, tri-, and tetranucleotide markers
tested showed loss of heterozygosity or allelic imbalance in
colorectal and other tumors (including breast carcinoma),
suggesting chromosomal instability (Fig. 2c). Immunohisto-
chemical analysis showed normal expression of MLH1
protein, the binding partner of MLH3 (ref. 4). One adenoma
of three tested revealed a BRAF-V600E variant in association
with CpG island methylator phenotype (see Supplementary
Materials and Methods).
Concurrent sequence changes in other genes from MLH3
variant carriers
Apart from the biallelic p.Ser1188Ter variant in MLH3, the
index patient from family 158 showed two MSH3 variants, a
truncating (c.1308_1309delAG, p.Glu437fs) and a missense
change (c.2692A>C, p.Asn898His) (Table S1). However, a
complementary DNA (cDNA) cloning experiment showed
that both variants affected the same allele; moreover, MSH3
protein was present in tumor tissue by immunohistochemical
analysis (Figure S3). High-penetrance heterozygous
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pathogenic germline variants of MSH3 are very rare in
individuals with a suspected cancer predisposition.5 Further-
more, family 158 with microsatellite-stable tumors showed no
evidence of a possible synergistic effect with other MMR gene
variants, as proposed to occur in some Lynch families.6
Therefore, heterozygosity for theMSH3 variants in family 158
is likely to represent a secondary finding. The index case from
family 168 carried a potentially pathogenic7 splice variant in
CHEK2 (c.319+2T>A), but it was absent in her affected
siblings. The lack of additional convincingly or likely
pathogenic germline variants by ES suggested that the biallelic
MLH3 p.Ser1188Ter variant was the primary alteration
behind polyposis in families 158, 168, and 177.
MMR gene variants found in index cases without theMLH3
founder variant
Based on clinical presentation as polyposis patients, previous
diagnostic tests conducted on the 40 polyposis cases from
Finland
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Fig. 1 Discovery of the pathogenic MLH3 variant in five polyposis families (a) Flow-chart of this investigation including the Finnish and Swedish
arms. MLH3 findings and methods used for their identification are shown. (b) Pedigrees of polyposis families with the MLH3 p.Ser1188Ter variant. Families
158, 168, 177, and 1007 are from Finland and family SWE is from Sweden. The pedigrees were generated with Pedigree Chart Designer. Numbers below
the symbols are patient identifiers. Arrow denotes the index person. Carrier status for the MLH3 c.3563C>G, p.Ser1188Ter variant is shown (+/+,
homozygous carrier, +/− heterozygous carrier). Tumor manifestations and age at diagnosis (years) are given below the patient symbol. AFAP attenuated
familial adenomatous polyposis, ES exome sequencing, FAP familial adenomatous polyposis, LS Lynch syndrome.
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Finland focused on established polyposis-associated genes.
Our exome sequencing experiments identified rare hetero-
zygous variants in the LS predisposition gene MSH2 in two
cases. Both variants involved the evolutionarily conserved
MSH3/MSH6 interaction domain of the MSH2 gene product
and were absent in disease- or locus-specific databases. The
index individual from family 1001 (with polyp count 10 and a
personal and family history of colorectal cancer) had a 27-bp
in-frame deletion (c.1140_1166del, p.Leu381_Arg389del)
likely to have pathogenic significance because it was
accompanied by MSI-high and absent MSH2 and MSH6
proteins in tumor tissue. The index individual from family
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Fig. 2 Origin and molecular characteristics of the MLH3 p.Ser1188Ter variant (a) Shared founder haplotype in carriers of the MLH3 p.Ser1188Ter
variant. The haplotypes for an 8.8-Mb region between microsatellite markers D14S268 and D14S1000 are shown for the index patients from the indicated
families (158, 168, 177, and SWE, homozygous carriers; 1007, heterozygous carrier). The conserved disease haplotype associated with the p.Ser1188Ter
variant (between positions 73,271,847 and 75,777,880) is shaded. Deviation from the conserved haplotype at D14S1047 in SWE could result from either
mutation or recombination. A core haplotype of 0.8Mb (between D14S1047 and D14S284) that includes the MLH3 gene and is shared by all p.Ser1188Ter
variant carriers is indicated by brackets. (b) Location of the p.Ser1188Ter variant relative to the main functional domains of MLH3. A lollipop diagram of the
MLH3 protein was created by MutationMapper. The functional domains are as follows: ATPase domain, MMR (DNA mismatch repair domain), and MutL_C
(MutL C terminal dimerization domain). (c) Results from microsatellite instability (MSI) and allelic imbalance (AI)/loss of heterozygosity (LOH) analyses of
colorectal adenomas from MLH3 p.Ser1188Ter variant carriers. The markers used were BAT25 (mononucleotide repeat from chromosome 4), D17S250
(dinucleotide repeat from chromosome 17), and D9S242 (tetranucleotide repeat from chromosome 9). All tumors were microsatellite-stable (MSS, mar-
ker BAT25). Allelic imbalance was evident with D17S250 and D9S242.
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1025 (a sporadic case with polyp count 20–30) revealed a
missense change (c.1337A>G, p.Asp446Gly) predicted dele-
terious by all six in silico programs tested. However, as the
variant was associated with stable microsatellites and normal
MMR protein expression in tumor tissue, its significance
remains unknown.
DISCUSSION
We describe a novel polyposis and cancer syndrome
associated with biallelic (homozygous) pathogenic germline
variant of the “minor” MMR gene MLH3. MLH3 was
originally identified as a colon tumor susceptibility gene in
mice some 20 years ago.8 A few dozen heterozygous germline
variants in MLH3 with possible pathogenicity, mostly
missense but also truncating, are listed in the InSiGHT
database (www.insight-group.org). The clinical significance of
such variants remains unsettled; they may play a role in
familial nonpolypotic colon cancer or LS predisposition
(MIM 614385) (refs. 9,10). MSI findings from tumor tissues
vary from instability at primarily di- and tetranucleotide
repeats9 to no MSI.10 Cosegregation results are variable and a
role as a low-penetrance colon cancer susceptibility gene has
been suggested.10,11 Due to the lack of genome-wide
sequencing data, concurrent pathogenic variants in other
cancer-relevant genes cannot often be excluded. No increased
risk of colorectal adenomas in putative LS families withMLH3
variants has been reported.9,10
Our results link a biallelic germline nonsense variant of
MLH3 to a clinical and molecular phenotype different from
LS: microsatellite-stable adenomatous polyposis exhibiting
chromosomal instability. Whether or not the rate of LOH/AI
in MLH3 variant carriers exceeds that observed in the
corresponding sporadic tumors remains to be addressed by
future studies. Moreover, the somatic BRAF-V600E variant
was detected in one of three adenomas from MLH3 p.
Ser1188Ter variant carriers, which is another discriminating
feature since BRAF-V600E generally predicts the absence of
LS.12 The lack of MSI in the MLH3 variant carriers is
compatible with the reported minor role for the MLH1-
MLH3 complex (hMutLγ) in MMR, reflecting redundancy
with the main MMR complex MLH1-PMS2 (hMutLα).4 The
accumulated data from yeast, mouse, and human cells suggest
a primary function for MLH3 in meiotic recombination
instead of MMR.13–15 Extrapolation from literature data
allows us to hypothesize that relevant functions that may fail
in the MLH3 p.Ser1188Ter-associated tumorigenesis might
involve, for example, DNA damage response (defective in
Mlh3−/− mice)14 or recombination-related processes.16
LS associated with “major” MMR genes MLH1, MSH2,
MSH6, and PMS2 can occasionally present with polyposis.
Two index cases from the Finnish polyposis series (2/40, 5%),
both with attenuated polyposis, revealed novel MMR gene
variants in MSH2 by exome sequencing. The findings comply
with Kalady et al.17 and suggest that although ten or more
adenomas prompt testing for polyposis, the possibility of LS
should not be overlooked.
While heterozygous sequence changes of MLH1, MSH2,
MSH6, and PMS2 can cause predisposition to LS, biallelic
inactivation of the same genes underlies constitutional MMR
deficiency syndrome (CMMRD; MIM 276300). CMMRD is
characterized by variable penetrance and diverse clinical
manifestations, including colonic adenomatous polyposis of
variable degree.18 Clinically, the MLH3-associated syndrome
we describe shares certain CMMRD features in analogy to the
MSH3-associated polyposis syndrome identified recently.5
The age at onset of polyposis (classical or attenuated) was
relatively late (48–52 years in the biallelic index cases), which
might suggest reduced penetrance. The cases were considered
sporadic relative to polyposis, but the family histories did
include various noncolonic cancers, especially breast cancer
(Fig. 1b). Breast cancer co-occurred with polyposis in the
index patient (III.3) from family 168 and was the only tumor
manifestation in her sister (III.2), likewise homozygous for the
MLH3 founder variant. While the possibility of the (post-
menopausal) breast carcinomas being phenocopies cannot be
excluded, heterozygous (truncating) germline variants in
MLH3 identified by recent massive parallel sequencing studies
of breast cancer patients support an association between
MLH3 and breast cancer.19 The observation of brain tumors
in the mothers of the index cases of families 158 and 168 is
also of potential interest given that multiple MLH3 variants
have been reported to coexist in colon cancer patients from
families with LS-associated brain tumors.20 The fact that none
of the parents of our homozygous polyposis patients were
affected with polyposis is consistent with recessive inheri-
tance; however, two proven heterozygous individuals had a
disease phenotype (attenuated polyposis in II.2 from family
1007 and renal urothelial cancer in III.1 from family 168).
Because our data rely on a founder variant enriched in the
Finnish population, investigations on additional cohorts and
populations are warranted to establish the significance of
MLH3 as a polyposis-predisposing factor and to define the
tumor spectrum of the syndrome.
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